CompletedPhase 4

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

South Korea140 participantsStarted 2010-08-05

Plain-language summary

The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects who have been treated with the study drug at least once and completed safety follow-up. * Subjects who have been treated with the study drug at least once and completed the clinical efficacy assessment. Exclusion Criteria: * Subjects not treated with study drug at least once.

What they're measuring

Safety

Timeframe: 4 years

Trial details

NCT IDNCT01437982

SponsorBausch & Lomb Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-10-19

View on ClinicalTrials.gov More Conjunctivitis, Seasonal Allergic trials